BiotechTube

Dexamethasone Ophthalmic Suspension

Phase 3Terminated
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Inflammation Eye

Conditions

Inflammation Eye, Pain, Postoperative, Cataract

Trial Timeline

Dec 18, 2023 → May 9, 2024

NCT ID
NCT06128369

About Dexamethasone Ophthalmic Suspension

Dexamethasone Ophthalmic Suspension is a phase 3 stage product being developed by Oculis Holding AG for Inflammation Eye. The current trial status is terminated. This product is registered under clinical trial identifier NCT06128369. Target conditions include Inflammation Eye, Pain, Postoperative, Cataract.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06128369Phase 3Terminated

Competing Products

20 competing products in Inflammation Eye

See all competitors
ProductCompanyStageHype Score
ISV-305Sun PharmaceuticalPhase 3
77
ISV-303 + ISV-303 + DuraSite Vehicle + Xibrom™Sun PharmaceuticalPhase 1/2
41
ISV-303Sun PharmaceuticalPhase 3
77
ISV-305Sun PharmaceuticalPhase 3
77
ISV-303Sun PharmaceuticalPhase 3
77
Omaveloxolone Ophthalmic Suspension 1.0% + Omaveloxolone Opthalmic Suspension 0.5% + PlaceboAbbViePhase 2
52
fluticasone propionate + Comparator: Placebo to fluticasone + Comparator: Lipopolysaccharide (LPS) + Comparator: albuterolMerckPhase 1
33
MAS825 + PlaceboNovartisPhase 2
52
Secukinumab s.c. injectionNovartisApproved
85
etanerceptAmgenPhase 3
76
anti-IL-20 + placeboNovo NordiskPhase 1
32
NNC0114-0006 + placeboNovo NordiskPhase 2
51
NNC0114-0006 + placeboNovo NordiskPhase 1
32
NNC0109-0012 + placeboNovo NordiskPhase 2
51
NNC 0151-0000-0000 + NNC 0151-0000-0000 + placeboNovo NordiskPhase 1
32
catridecacog + placeboNovo NordiskPhase 2
51
NNC109-0012 + placeboNovo NordiskPhase 2
51
anti-IL-20 + placeboNovo NordiskPhase 1
32
NNC0215-0384 + placeboNovo NordiskPhase 1
32
NNC 0151-0000-0000 + placeboNovo NordiskPhase 2
51

Other Products from Oculis Holding AG

OCS-01 + VehiclePhase 3
72
Dexamethasone ophthalmic suspension (OCS-01) + VehiclePhase 3
72
Dexamethasone ophthalmic suspension (OCS-01) + VehiclePhase 2/3
60
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL + PlaceboPhase 2
47
OCS-01Phase 2
47